Logo image of RARE

ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

NASDAQ:RARE - Nasdaq - US90400D1081 - Common Stock - Currency: USD

42.59  -1.89 (-4.25%)

After market: 42.59 0 (0%)

Fundamental Rating

4

Overall RARE gets a fundamental rating of 4 out of 10. We evaluated RARE against 571 industry peers in the Biotechnology industry. The financial health of RARE is average, but there are quite some concerns on its profitability. RARE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RARE had negative earnings in the past year.
In the past year RARE has reported a negative cash flow from operations.
RARE had negative earnings in each of the past 5 years.
RARE had a negative operating cash flow in each of the past 5 years.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -36.34%, RARE is in line with its industry, outperforming 59.89% of the companies in the same industry.
RARE has a Return On Equity of -161.17%. This is in the lower half of the industry: RARE underperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -36.34%
ROE -161.17%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

RARE has a Gross Margin of 86.25%. This is amongst the best in the industry. RARE outperforms 89.30% of its industry peers.
RARE's Gross Margin has been stable in the last couple of years.
RARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

6

2. Health

2.1 Basic Checks

RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for RARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.91, we must say that RARE is in the distress zone and has some risk of bankruptcy.
RARE has a Altman-Z score (-1.91) which is comparable to the rest of the industry.
There is no outstanding debt for RARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.91
ROIC/WACCN/A
WACC9.51%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B

2.3 Liquidity

RARE has a Current Ratio of 2.81. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
RARE has a worse Current ratio (2.81) than 68.45% of its industry peers.
RARE has a Quick Ratio of 2.65. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
RARE has a worse Quick ratio (2.65) than 68.81% of its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.65
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.89% over the past year.
Looking at the last year, RARE shows a very strong growth in Revenue. The Revenue has grown by 29.00%.
RARE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.13% yearly.
EPS 1Y (TTM)23.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.55%
Revenue 1Y (TTM)29%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%29.43%

3.2 Future

RARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.94% yearly.
RARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.09% yearly.
EPS Next Y15.05%
EPS Next 2Y20.4%
EPS Next 3Y26.9%
EPS Next 5Y29.94%
Revenue Next Year19.14%
Revenue Next 2Y24.58%
Revenue Next 3Y32.94%
Revenue Next 5Y39.09%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
Also next year RARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

RARE's earnings are expected to grow with 26.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.4%
EPS Next 3Y26.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RARE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (2/21/2025, 8:00:01 PM)

After market: 42.59 0 (0%)

42.59

-1.89 (-4.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners97.3%
Inst Owner Change-94.97%
Ins Owners3.67%
Ins Owner Change-0.42%
Market Cap3.93B
Analysts84.62
Price Target96.31 (126.13%)
Short Float %4.73%
Short Ratio4.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.69%
Min EPS beat(2)5.37%
Max EPS beat(2)12.01%
EPS beat(4)3
Avg EPS beat(4)2.61%
Min EPS beat(4)-14.94%
Max EPS beat(4)12.01%
EPS beat(8)4
Avg EPS beat(8)-1.94%
EPS beat(12)4
Avg EPS beat(12)-15.33%
EPS beat(16)6
Avg EPS beat(16)-11.52%
Revenue beat(2)2
Avg Revenue beat(2)8.87%
Min Revenue beat(2)0.71%
Max Revenue beat(2)17.02%
Revenue beat(4)3
Avg Revenue beat(4)3.58%
Min Revenue beat(4)-8.03%
Max Revenue beat(4)17.02%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-1.88%
Revenue beat(16)7
Avg Revenue beat(16)1.78%
PT rev (1m)1.58%
PT rev (3m)2%
EPS NQ rev (1m)2.31%
EPS NQ rev (3m)4.27%
EPS NY rev (1m)-3.44%
EPS NY rev (3m)-3.4%
Revenue NQ rev (1m)6.11%
Revenue NQ rev (3m)5.91%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)1.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.52
P/FCF N/A
P/OCF N/A
P/B 11.34
P/tB 28.61
EV/EBITDA N/A
EPS(TTM)-6.34
EYN/A
EPS(NY)-5.39
Fwd EYN/A
FCF(TTM)-4.76
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS5.66
BVpS3.76
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.34%
ROE -161.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.25%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.36%
Cap/Sales 4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.65
Altman-Z -1.91
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.55%
EPS Next Y15.05%
EPS Next 2Y20.4%
EPS Next 3Y26.9%
EPS Next 5Y29.94%
Revenue 1Y (TTM)29%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%29.43%
Revenue Next Year19.14%
Revenue Next 2Y24.58%
Revenue Next 3Y32.94%
Revenue Next 5Y39.09%
EBIT growth 1Y9.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.02%
OCF growth 3YN/A
OCF growth 5YN/A